HRTX - Premarket Heats Up For This Biotech Before Opening Bell

2024-01-24 09:37:29 ET

A California-based %Biotech company is turning heads on Wednesday morning after it was announced that the company received FDA approval for the supplemental new drug application for %Zynrelef to include additional orthopedic and soft tissue procedures, according to a press release.

Shares of %HeronTherapeutics (Nasdaq: HRTX) were quickly bid up during premarket hours as traders are currently willing to buy shares at $2.29/share (+4.09% implied open for sellers) at the time of writing. This move will be a strong continuation of this stock’s success found over the last few weeks.

Heron Therapeutics Inc is a commercial-stage biotechnology company. It is focused on improving the lives of patients by developing treatments that address some of the unmet patient needs. The company's product portfolio consists of SUSTOL, ZYNRELEF, and CINVANTI. Its pipeline product is HTX-011.